D. E. Shaw & Co., Inc. Iovance Biotherapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 39,276 shares of IOVA stock, worth $86,799. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,276
Previous 30,812
27.47%
Holding current value
$86,799
Previous $228,000
42.98%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding IOVA
# of Institutions
334Shares Held
247MCall Options Held
1.34MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA27.8MShares$61.4 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$54 Million12.15% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$46.9 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY12.7MShares$28.1 Million1.77% of portfolio
-
State Street Corp Boston, MA11MShares$24.4 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $349M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...